Constructing narratives of heroism and villainy: Case study of Myriad's BRACAnalysis® compared to Genentech's Herceptin®

Genome Medicine

Volumn 5, Issue 1, 2013, Pages

  Baldwin, A L ^a   Cook Deegan, Robert ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TRASTUZUMAB;

ARTICLE; BIOTECHNOLOGY; BREAST CANCER; CANCER RISK; CLINICAL DECISION MAKING; COMPARATIVE STUDY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; FUNDING; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENETIC COUNSELING; GENETIC RISK; GENOMICS; HEALTH CARE; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; LAW SUIT; MEDICAL CARE; OVARY CANCER; PATENT; POLITICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84873034661     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm412     Document Type: Article

References (67)

1. Association for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010).
2. Vorhaus J. Pigs Fly: Federal Court Invalidates Myriad's Patent Claims. The Genomics Law Report 2010, 2012. Robinson Bradshaw & Hinson, PA, Vorhaus D.
3. Association for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011).
4. Petition for Writ of Certiorari, Ass'n for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398, (U.S. Sept. 25, 2012).
5. Docket Files for Association of Molecular Pathology, et al. v. Myriad Genetics Inc., et al. , http://www.supremecourt.gov/Search.aspx?FileName=/docketfiles/11-725.htm
6. Docket Files for the Association of Molecular Pathology et al. v. Myriad Genetics Inc., et al. , http://www.supremecourt.gov/Search.aspx?FileName=/docketfiles/12-398.htm
7. Eisenberg R. How can you patent genes?. American Journal of Bioethics 2002, 2:3-11.
8. Parthasarathy S. Building Genetic Medicine: Breast Cancer, Technology, and the Comparative Politics of Healthcare. 2007, Cambridge, MA: MIT Press.
9. Gold ER, Carbone J. Myriad Genetics: In the eye of the policy storm. Genetics in medicine: official journal of the American College of Medical Genetics 2010, 12:S39-70.
10. Davies K, White M. Breakthrough: the race to find the breast cancer gene. 1996, 310.
11. Williams-Jones B. History of a gene patent: tracing the development and application of commercial BRCA testing. Health Law Journal 2002, 10:123-146.
12. Caulfield T, Cook-Deegan RM, Kieff FS, Walsh JP. Evidence and anecdotes: an analysis of human gene patenting controversies. Nat Biotechnol 2006, 24:1091-1094. 10.1038/nbt0906-1091, 2701726, 16964215.
13. Caulfield T, Bubela T, Murdoch CJ. Myriad and the mass media: the covering of a gene patent controversy. Genet Med 2007, 9:850-855. 10.1097/GIM.0b013e31815bf965, 18091435.
14. Genentech and Chairman/CEO Levinson to Receive National Breast Cancer Coalition's Corporate Leadership Award. , http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=4890
15. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983, 306:234-238. 10.1038/306234a0, 6316146.
16. Stephens JC, Mador ML, Cavanaugh ML, Gradie MI, Kidd KK. Mapping the Human Genome: Current Status. Science 1990, 250:237-244. 10.1126/science.2218527, 2218527.
17. Roberts L. The rush to publish. Science 1991, 251:260-263. 10.1126/science.1898994, 1898994.
18. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265:2088-2090. 10.1126/science.8091231, 8091231.
19. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792. 10.1038/378789a0, 8524414.
20. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature genetics 1996, 12:333-337. 10.1038/ng0396-333, 8589730.
21. Tavtigian et al. Chromosome 13-Linked Breast Cancer Susceptibility Gene. US Patent 6,033,857. Filed March 20, 1998 and issued March 7, 2000.
22. A. Futreal et al. Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof. US Patent 6,045,997. Filed November 25, 1996 and issued April 4, 2000.
23. D. Shattuck-Eidens, et al. Linked Breast and Ovarian Cancer Susceptibility Gene. US Patent 5,693,473. Filed June 7, 1995 and issued December 2, 1997. In.
24. Cook-Deegan R, DeRienzo C, Carbone J, Chandrasekharan S, Heaney C, Conover C. Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers. Genet Med 2010, 12:S15-38. 3047448, 20393305.
25. BRACAnalysis. , http://www.bracnow.com/
26. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 1998, 90:1371-1388. 10.1093/jnci/90.18.1371, 9747868.
27. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. The New England journal of medicine 2002, 346:1609-1615. 10.1056/NEJMoa020119, 12023992.
28. John Conley DV, Robert C-D. How Will Myriad Respond to the Next Generation of BRCA Testing?. Genomics Law Report 2011, 2012. Robinson, Bradshaw, & Hinson PA, Vorhaus D.
29. Myriad Genetics Laboratories I Myriad Genetics SEC Annual Report, Form 10-K. 2012, Washington, D.C.: United States Securities and Exchange Commission, Myriad Genetics Laboratories I.
30. Bazell R. Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer. 1998, 240.
31. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
32. Szabo L. Breakout drug Herceptin brings new age in breast cancer care. USA Today 2008, Gannett Company Inc..
33. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England journal of medicine 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737.
34. Genentech Announces Full Year and Fourth Quarter 2008 Results. , http://www.sec.gov/Archives/edgar/data/318771/000031877109000002/ex99_1.htm
35. Bosklopper E. Antibody Drugs: Technologies and Global Markets. 2012, Wellesley, MA: BCC Research.
36. Association for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010). Declaration of Arupa Ganguly, Ph.D. , http://www.aclu.org/files/pdfs/freespeech/brca_Ganguly_declaration_20090826.pdf
37. Klausner, Richard and Critchfield, Gregory Memorandum of Understanding between Myriad Genetics, Inc. And the National Cancer Institute. 1999, Salt Lake City, UT: Myriad Genetics and the National Cancer Institute, Klausner, Richard and Critchfield, Gregory.
38. Eisenberg R. Public Research and Private Development: Patents and Technology Transfer in Government-Sponsored Research. Virginia Law Review 1996, 82:1663-1727.
39. Mueller J. The Evanescent Experimental Use Exemption from the United States Patent Infringement Liability: Implications for University and Nonprofit Research and Development. Baylor Law Review 2004, 56:917-981.
40. Twitter report from the Genomes, Environments, Traits (GET) Conference, Boston, MA, April 27, 2010. , http://www.genomicslawreport.com/wp-content/plugins/as-pdf/generate.php?post=3231
41. Rebecca Farkas DG, Margaret E. Myriad and OncorMed and the marketing of the first genetic tests for breast cancer susceptibility. 2004, Palo Alto, California: Stanford Graduate School of Business.
42. Cho MK, Illangasekare S, Weaver MA, Leonard DG, Merz JF. Effects of patents and licenses on the provision of clinical genetic testing services. J Mol Diagn 2003, 5:3-8. 10.1016/S1525-1578(10)60444-8, 1907368, 12552073.
43. Friedman S. Testimony to USPTO on impact of exclusive gene patents. 2012, Facing Our Risk of Cancer Empowered.
44. An Open Access On-Line Breast Cancer Mutation Data Base. , http://research.nhgri.nih.gov/bic/
45. Cook-Deegan R, Conley JM, Evans JP, Vorhaus D. The next controversy in genetic testing: clinical data as trade secrets?. European journal of human genetics: EJHG 2012,
46. USPTO Roundtable Written Commentary. , http://www.facingourrisk.org/advocacy/current_action/documents/USPTO_Jan2013_Written_Testimony.pdf
47. Azvolinsky A. Lack of BRCA testing approval creates snag for cancer trials. Nature medicine 2012, 18:1310.
48. Testimony to USPTO on impact on exclusive gene patents. , http://www.facingourrisk.org/advocacy/current_action/uspto_update.php
49. Elizabeth Swisher M. Association for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010).Declaration of Elizabeth Swisher, MD. 2009, United States District Court.
50. Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer research 2008, 68:7006-7014. 10.1158/0008-5472.CAN-08-0599, 2752710, 18703817.
51. Ellen Matloff RB, Danielle B, et al. An Open Letter to Myriad Genetics. 2011, New Haven, Connecticut: Yale Cancer Genetic Counseling, Richard Wenstrup M.
52. Cohen E. When breast cancer test gets it wrong. 2011, CNN Health: CNN.
53. NBCC Responds to ODAC Vote on Avastin®. , http://www.knowbreastcancer.org/news-research/news/nbcc-response-to-odac-vote-on.html
54. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1996, 14:1730-1736. discussion 1737-1740.
55. Frances Visco MS, Francis Collins Commentary on the ASCO Statement on Genetic Testing for Cancer Susceptibility. 1996, American Society of Clinical Oncology, Oncology ASoC, Frances Visco MS, Francis Collins.
56. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, Swisher EM, King MC. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:12629-12633. 10.1073/pnas.1007983107, 2906584, 20616022.
57. Kepler TB, Crossman C, Cook-Deegan R. Metastasizing patent claims on BRCA1. Genomics 2010, 95:312-314. 10.1016/j.ygeno.2010.03.003, 2857658, 20226239.
58. Scholl, et al. BRCA2 Mutations and Use Thereof, US Patent 7,993,835. 2011, Issued by United States Patent and Trade Office. USA: Myriad Genetics, Inc..
59. Robert Cook-Deegan JC, James E, Daniel V. The Next Controvery in Genetic Testing: Clinical Data as Trade Secrets?. European Journal of Human Genetics 2012, (forthcoming).
60. What Happened at the Fda Avastin Meeting?. , http://www.clinicaloncology.com/ViewArticle.aspx?d=Solid+Tumors&d_id=148&i=August+2011&i_id=757&a_id=18820.%5D
61. Linn A. As They Lay Dying. San Francisco Weekly 1995, San Francisco: Village Voice Media Holdings, LLC.
62. NBCC President Praises Genentech for Partnering With Breast Cancer Advocates in HER-2 Trial. , http://www.cancernetwork.com/display/article/10165/64743
63. Comment 43: National Breast Cancer Coalition/Fran Visco. , http://www.uspto.gov/web/offices/com/sol/comments/utilguide/nbcc.pdf
64. Association for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010).Declaration of Dr. Mark Skolnick. , http://docs.justia.com/cases/federal/district-courts/new-york/nysdce/1:2009cv04515/345544/172/0.pdf?ts=1262043961
65. Take Back Your Genes | American Civil Liberties Union. , http://www.aclu.org/take-back-your-genes
66. Watson J. Brief for Amicus Curiae James D. Watson in Support of Neither Party. 2012, United States Court of Appeals for the Federal Circuit., http://www.genome.duke.edu/centers/cpg/BRCA-resources/documents/WatsonAmicus.pdf
67. Lenzer J, Brownlee S. Naming names: is there an (unbiased) doctor in the house?. BMJ 2008, 337:a930. 10.1136/bmj.a930, 18650241.